Pyridobenzodiazepines: a novel class of orally active, vasopressin V2 receptor selective agonists

  • Bioorg Med Chem Lett. 2006 Feb 15;16(4):954-9. doi: 10.1016/j.bmcl.2005.10.107.
Amedeo A Failli  1 ,  Jay S Shumsky ,  Robert J Steffan ,  Thomas J Caggiano ,  David K Williams ,  Eugene J Trybulski ,  Xiaoping Ning ,  Yeungwai Lock ,  Tarak Tanikella ,  David Hartmann ,  Peter S Chan ,  C H Park
Affiliations
  • 1. Chemical and Screening Sciences, Wyeth Research, CN 8000, Princeton, NJ 08543-8000, USA. [email protected]
PMID: 16297621 DOI: 10.1016/j.bmcl.2005.10.107
Abstract

Our efforts in seeking low molecular weight agonists of the antidiuretic peptide hormone arginine vasopressin (AVP) have led to the identification of the clinical candidate WAY-151932 (VNA-932). Further exploration of the structural requirements for agonist activity has provided another class of potent, orally active, non-peptidic vasopressin V2 receptor selective agonists exemplified by the 5,11-dihydro-pyrido[2,3-b][1,5]benzodiazepine as a candidate for further development.

Products